Anuj Shah1, Corey J Hayes2,3, Mrinmayee Lakkad2, Bradley C Martin4. 1. Pharmerit International, Bethesda, MD, USA. 2. Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 3. Division of Health Services Research, Psychiatric Research Institute, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 4. Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. bmartin@uams.edu.
Abstract
OBJECTIVE: To determine the association of medical marijuana legalization with prescription opioid utilization. METHODS: A 10% sample of a nationally representative database of commercially insured population was used to gather information on opioid use, chronic opioid use, and high-risk opioid use for the years 2006-2014. Adults with pharmacy and medical benefits for the entire calendar year were included in the population for that year. Multilevel logistic regression analysis, controlling for patient, person-year, and state-level factors, were used to determine the impact of medical marijuana legalization on the three opioid use measures. Sub-group analysis among cancer-free adults and cancer-free adults with at least one chronic non-cancer pain condition in the particular year were conducted. Alternate regression models were used to test the robustness of our results including a fixed effects model, an alternate definition for start date for medical marijuana legalization, a person-level analysis, and a falsification test. RESULTS: The final sample included a total of 4,840,562 persons translating into 15,705,562 person years. Medical marijuana legalization was found to be associated with a lower odds of any opioid use: OR = 0.95 (0.94-0.96), chronic opioid use: OR = 0.93 (0.91-0.95), and high-risk opioid use: OR = 0.96 (0.94-0.98). The findings were similar in both the sub-group analyses and all the sensitivity analyses. The falsification tests showed no association between medical marijuana legalization and prescriptions for antihyperlipidemics (OR = 1.00; CI 0.99-1.01) or antihypertensives (OR = 1.00; CI 0.99-1.01). CONCLUSIONS: In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Policy makers could consider medical marijuana legalization as a tool that may modestly reduce chronic and high-risk opioid use. However, further research assessing risk versus benefits of medical marijuana legalization and head to head comparisons of marijuana versus opioids for pain management is required.
OBJECTIVE: To determine the association of medical marijuana legalization with prescription opioid utilization. METHODS: A 10% sample of a nationally representative database of commercially insured population was used to gather information on opioid use, chronic opioid use, and high-risk opioid use for the years 2006-2014. Adults with pharmacy and medical benefits for the entire calendar year were included in the population for that year. Multilevel logistic regression analysis, controlling for patient, person-year, and state-level factors, were used to determine the impact of medical marijuana legalization on the three opioid use measures. Sub-group analysis among cancer-free adults and cancer-free adults with at least one chronic non-cancer pain condition in the particular year were conducted. Alternate regression models were used to test the robustness of our results including a fixed effects model, an alternate definition for start date for medical marijuana legalization, a person-level analysis, and a falsification test. RESULTS: The final sample included a total of 4,840,562 persons translating into 15,705,562 person years. Medical marijuana legalization was found to be associated with a lower odds of any opioid use: OR = 0.95 (0.94-0.96), chronic opioid use: OR = 0.93 (0.91-0.95), and high-risk opioid use: OR = 0.96 (0.94-0.98). The findings were similar in both the sub-group analyses and all the sensitivity analyses. The falsification tests showed no association between medical marijuana legalization and prescriptions for antihyperlipidemics (OR = 1.00; CI 0.99-1.01) or antihypertensives (OR = 1.00; CI 0.99-1.01). CONCLUSIONS: In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Policy makers could consider medical marijuana legalization as a tool that may modestly reduce chronic and high-risk opioid use. However, further research assessing risk versus benefits of medical marijuana legalization and head to head comparisons of marijuana versus opioids for pain management is required.
Entities:
Keywords:
chronic opioid use; marijuana; medical marijuana legalization; opioids; pain
Authors: Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander Journal: Med Care Date: 2013-10 Impact factor: 2.983
Authors: Harry L Leider; Jatinder Dhaliwal; Elizabeth J Davis; Mahesh Kulakodlu; Ami R Buikema Journal: Am J Manag Care Date: 2011-01 Impact factor: 2.229
Authors: Ellen Meara; Jill R Horwitz; Wilson Powell; Lynn McClelland; Weiping Zhou; A James O'Malley; Nancy E Morden Journal: N Engl J Med Date: 2016-06-22 Impact factor: 91.245
Authors: Kayla N Tormohlen; Mark C Bicket; Sarah White; Colleen L Barry; Elizabeth A Stuart; Lainie Rutkow; Emma E McGinty Journal: Curr Addict Rep Date: 2021-09-28
Authors: Rachel Carmen Ceasar; Alex H Kral; Kelsey Simpson; Lynn Wenger; Jesse L Goldshear; Ricky N Bluthenthal Journal: Drug Alcohol Depend Date: 2020-11-23 Impact factor: 4.492
Authors: Lynn M Neilson; Caroline Swift; Elizabeth C S Swart; Yan Huang; Natasha Parekh; Kiraat D Munshi; Rochelle Henderson; Chester B Good Journal: J Gen Intern Med Date: 2021-02-11 Impact factor: 5.128
Authors: Jan M Schilling; Chloe G Hughes; Mark S Wallace; Michelle Sexton; Miroslav Backonja; Tobias Moeller-Bertram Journal: J Pain Res Date: 2021-05-05 Impact factor: 3.133
Authors: William C Goedel; Alexandria Macmadu; Abdullah Shihipar; Patience Moyo; Magdalena Cerdá; Brandon D L Marshall Journal: Int J Drug Policy Date: 2021-10-23